Solventum upgraded by BTIG Research with a new price target
$SOLV
Medical/Dental Instruments
Health Care
BTIG Research upgraded Solventum from Neutral to Buy and set a new price target of $100.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $100.00 | Neutral → Buy | BTIG Research |
| 10/1/2025 | $77.00 | Neutral | UBS |
| 9/11/2025 | $80.00 | Hold | Jefferies |
| 7/15/2025 | $103.00 | Equal-Weight → Overweight | Morgan Stanley |
| 7/1/2025 | $90.00 | Hold → Buy | Argus |
| 6/6/2025 | Sector Weight | KeyBanc Capital Markets | |
| 5/19/2025 | $87.00 | Neutral → Overweight | Piper Sandler |
| 12/4/2024 | $70.00 | Neutral | Mizuho |
BTIG Research upgraded Solventum from Neutral to Buy and set a new price target of $100.00
UBS initiated coverage of Solventum with a rating of Neutral and set a new price target of $77.00
Jefferies initiated coverage of Solventum with a rating of Hold and set a new price target of $80.00
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
8-K - Solventum Corp (0001964738) (Filer)
SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)
10-Q - Solventum Corp (0001964738) (Filer)
Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care. "Announcing and completing our first strategic ac
New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care Solventum™ Prevena™ Therapy is the only closed incision negative pressure therapy system with fully integrated linear and area dressings solely indicated for closed incisions that utilize ROCF technology ST. PAUL, Minn., Dec. 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the consensus recommendations of an international, multidisciplinary panel of surgeons and wound care experts on the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dr
ST. PAUL, Minn., Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC), the highest recognition for supply chain strength in healthcare. This certification validates Solventum's MedSurg segment's ability to deliver critical healthcare products consistently, even during supply disruptions to help ensure uninterrupted patient care. "The Diamond Level Resiliency Badge represents the highest standard in healthcare supply chain resiliency and operationa
Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care. "Announcing and completing our first strategic ac
Reported sales increased 0.7%; organic sales increased 2.7%Expects full year organic sales growth to be at the high end of +2.0% to +3.0% rangeIncreases full year adjusted earnings per share outlook to $5.98 to $6.08Announces 4-year 'Transform for the Future' initiativeST. PAUL, Minn., Nov. 6, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Sales increased 0.7% to $2.1 billion; up 2.7% on an organic basisGAAP diluted earnings per share of $7.22; adjusted diluted earnings p
ST. PAUL, Minn., Oct. 16, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter fiscal 2025 financial results on Thursday, Nov. 6, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Nov. 6, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (6
ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sale
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza
SC 13G/A - Solventum Corp (0001964738) (Subject)
SC 13G/A - Solventum Corp (0001964738) (Subject)